| 应用 |
A cholesterol reducing compound that also inhibits CYP |
| 产品介绍 |
Avasimibe抑制ACAT，IC50为3.3 μM，也抑制人P450同工酶CYP2C9， CYP1A2和CYP2C19，IC50分别为2.9 μM， 13.9 μM和26.5 μM |
| 合法信息 |
Sold for only research purposes |
| 备注 |
Avasimibe inhibits ACAT with IC50 of 3.3 μM, also inhibits human P450 isoenzymes CYP2C9, CYP1A2 and CYP2C19 with IC50 of 2.9 μM, 13.9 μM and 26.5 μM, |
| 生化机理 |
Avasimibe inhibits human P450 isoenzymes, particularly CYP2C9, CYP1A2 and CYP2C19, with an IC50 of 2.9μM, 13.9 μM, and 26.5 μM, respectively. These enzymes are responsible for a variety of oxidative metabolic reactions. |
| 别名 |
阿伐麦布; N-(2,6-二异丙基苯氧基)磺酰-2-(2,4,6-三异丙基苯基)乙酰胺;CI-1011; PD 148515;CI-1011; PD 148515; [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester] sulfamic acid;N-(2,6-Dipropan-2-ylphenoxy)sulfonyl-2-(2,4,6-tripropan-2-ylphenyl)acetamide |
